• Ying Ying Leung, Ana-Maria Orbai, Alexis Ogdie, Laura C Coates, Maarten de Wit, Callis Duffin Kristina K https://orcid.org/0000-0002-5464-0439 From the Duke-NUS Medical School, Singapore; Department of Rheumatology and Immunology,, Lihi Eder, Dafna D Gladman, Niti Goel, Philip J Mease, Vibeke Strand, Oliver FitzGerald, and William Tillett.
• From the Duke-NUS Medical School, Singapore; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah; Kezar Life Sciences, San Francisco; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam, the Netherlands; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland. katyccc@hotmail.com.
• J Rheumatol Suppl. 2019 Jun 1; 95: 33-37.

AbstractThe Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Working Group reported at the 2018 GRAPPA annual meeting on the outcome of the OMERACT 2018 Conference in Terrigal, Australia. The working group presented the endorsement of the 66/68 joint count for the assessment of peripheral arthritis and the provisional endorsement of the PsA Impact of Disease 12 questionnaire for the assessment of PsA-specific health-related quality of life in PsA randomized controlled trials and observational studies. In this report, the group presents its plan to seek OMERACT endorsement for outcome measures that address the domains of MSK disease activity for enthesitis and dactylitis, physical function, fatigue, and structural damage following the OMERACT Filter 2.1 methodology.

19 keywords...

hide…